Gelatin Microspheres Based on H8-Loaded Macrophage Membrane Vesicles to Promote Wound Healing in Diabetic Mice
Source abstract
Abstract
Diabetic wound healing remains a worldwide challenge for both clinicians and researchers. The high expression of matrix metalloproteinase 9 (MMP9) and a high inflammatory response are indicative of poor diabetic wound healing. H8, a curcumin analogue, is able to treat diabetes and is anti-inflammatory, and our pretest showed that it has the potential to treat diabetic wound healing. However, H8 is highly expressed in organs such as the liver and kidney, resulting in its unfocused use in diabetic wound targeting. (These data were not published, see Table S1 in the Supporting Information.) Accordingly, it is important to pursue effective carrier vehicles to facilitate the therapeutic uses of H8. The use of H8 delivered by macrophage membrane-derived nanovesicles provides a potential strategy for repairing diabetic wounds with improved drug efficacy and fast healing. In this study, we fabricated an injectable gelatin microsphere (GM) with sustained MMP9-responsive H8 macrophage membrane-derived nanovesicles (H8NVs) with a targeted release to promote angiogenesis that also reduces oxidative stress damage and inflammation, promoting diabetic wound healing. Gelatin microspheres loaded with H8NV (GMH8NV) stimulated by MMP9 can significantly facilitate the migration of NIH-3T3 cells and facilitate the development of tubular structures by HUVEC in vitro . In addition, our results demonstrated that GMH8NV stimulated by MMP9 protected cells from oxidative damage and polarized macrophages to the M2 phenotype, leading to an inflammation inhibition. By stimulating angiogenesis and collagen deposition, inhibiting inflammation, and reducing MMP9 expression, GMH8NV accelerated wound healing. This study showed that GMH8NVs were targeted to release H8NV after MMP9 stimulation, suggesting promising potential in achieving satisfactory healing in diabetic treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Wound Healing and Treatments · Periodontal Regeneration and Treatments · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Life Science, Mudanjiang Medical University, Mudanjiang 157011, People’s Republic of China
Clinical Laboratory, Maoming Third People’s Hospital, Maoming 525000, People’s Republic of China
Funding
Natural Science Foundation of Heilongjiang Province · Torch Program of Mudanjiang Medical College Science Foundation · Heilongjiang Provincial Department of Finance
References (61)
Show source-provided references
1. 10.2174/13892030978731520210.2174/138920309787315202 ↗
2. 10.3389/fphar.2019.0042110.3389/fphar.2019.00421 ↗
3. 10.2522/ptj.2008002010.2522/ptj.20080020 ↗
4. 10.1016/j.jcma.2017.11.00210.1016/j.jcma.2017.11.002 ↗
5. 10.3389/fphar.2019.0109910.3389/fphar.2019.01099 ↗
6. 10.2147/IJN.S27600110.2147/IJN.S276001 ↗
7. 10.7150/thno.2976610.7150/thno.29766 ↗
8. 10.1021/acsami.1c0988910.1021/acsami.1c09889 ↗
9. 10.1016/j.mtbio.2022.10036510.1016/j.mtbio.2022.100365 ↗
10. 10.2147/IJN.S21032010.2147/IJN.S210320 ↗
11. 10.1039/C7FO01242J10.1039/C7FO01242J ↗
12. 10.1177/088532821986092910.1177/0885328219860929 ↗
13. 10.1016/j.ejmech.2014.03.01210.1016/j.ejmech.2014.03.012 ↗
14. 10.1016/j.ejphar.2016.05.03410.1016/j.ejphar.2016.05.034 ↗
15. 10.1016/j.colsurfb.2016.11.03610.1016/j.colsurfb.2016.11.036 ↗
16. 10.3390/pharmaceutics1203022610.3390/pharmaceutics12030226 ↗
17. 10.3390/ph1408081110.3390/ph14080811 ↗
18. 10.1038/nrm.2017.12510.1038/nrm.2017.125 ↗
19. 10.1016/j.biopha.2021.11258610.1016/j.biopha.2021.112586 ↗
20. 10.2217/nnm-2017-010010.2217/nnm-2017-0100 ↗
21. 10.1186/s12951-022-01746-610.1186/s12951-022-01746-6 ↗
22. 10.1016/j.ajps.2021.11.00110.1016/j.ajps.2021.11.001 ↗
23. 10.3390/pharmaceutics1107031410.3390/pharmaceutics11070314 ↗
24. 10.1211/002235700177444410.1211/0022357001774444 ↗
25. 10.2337/db17-123810.2337/db17-1238 ↗
26. 10.1111/wrr.1203510.1111/wrr.12035 ↗
27. 10.1111/j.1365-2133.2008.08462.x10.1111/j.1365-2133.2008.08462.x ↗
28. 10.1021/acsami.8b0386810.1021/acsami.8b03868 ↗
29. 10.1021/nl500618u10.1021/nl500618u ↗
30. 10.3390/nu1411235810.3390/nu14112358 ↗
31. 10.1186/s12967-021-03156-y10.1186/s12967-021-03156-y ↗
32. 10.1016/j.bioactmat.2022.01.00410.1016/j.bioactmat.2022.01.004 ↗
33. 10.1016/j.nano.2022.10253810.1016/j.nano.2022.102538 ↗
34. 10.1016/j.ijbiomac.2019.10.23610.1016/j.ijbiomac.2019.10.236 ↗
35. 10.1002/adma.20150356510.1002/adma.201503565 ↗
36. 10.1007/s00280-010-1470-210.1007/s00280-010-1470-2 ↗
37. 10.1007/s11523-014-0321-110.1007/s11523-014-0321-1 ↗
38. 10.1177/002203450935912510.1177/0022034509359125 ↗
39. 10.1016/j.devcel.2021.03.02010.1016/j.devcel.2021.03.020 ↗
40. 10.1089/wound.2013.051710.1089/wound.2013.0517 ↗
41. 10.1186/s13287-020-01824-210.1186/s13287-020-01824-2 ↗
42. 10.1186/s12951-021-00894-510.1186/s12951-021-00894-5 ↗
43. 10.1080/10717544.2018.142577410.1080/10717544.2018.1425774 ↗
44. 10.1155/2021/128508710.1155/2021/1285087 ↗
45. 10.1089/ars.2017.726310.1089/ars.2017.7263 ↗
46. 10.2147/IJN.S17407210.2147/IJN.S174072 ↗
47. 10.1371/journal.pone.023037410.1371/journal.pone.0230374 ↗
48. 10.1093/burnst/tkac04610.1093/burnst/tkac046 ↗
49. 10.4049/jimmunol.170022310.4049/jimmunol.1700223 ↗
50. 10.3390/molecules2616491710.3390/molecules26164917 ↗
51. 10.1016/j.trsl.2021.05.00610.1016/j.trsl.2021.05.006 ↗
52. 10.3389/fmed.2021.77552310.3389/fmed.2021.775523 ↗
53. 10.3390/nano1006123410.3390/nano10061234 ↗
54. 10.3390/cells1003065510.3390/cells10030655 ↗
55. 10.2337/dc08-076310.2337/dc08-0763 ↗
56. 10.1016/j.phrs.2016.03.00810.1016/j.phrs.2016.03.008 ↗
57. 10.3390/biomedicines1011290210.3390/biomedicines10112902 ↗
58. 10.1016/j.bioactmat.2022.06.01810.1016/j.bioactmat.2022.06.018 ↗
59. 10.1002/advs.20210331710.1002/advs.202103317 ↗
60. 10.3390/pharmaceutics1410206510.3390/pharmaceutics14102065 ↗
61. 10.1001/jamanetworkopen.2021.2260710.1001/jamanetworkopen.2021.22607 ↗